NME Submissions See “Modest” Rise In 2005 – Parexel’s Bio/Pharma Report
Executive Summary
New molecular entity submissions reached a six-year high in 2005, a slight increase from the previous year, according to Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2006/2007
You may also be interested in...
Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18
The first half of 2006 could bring at least five novel oncologic approvals, including three for hematologic cancers
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials